Zepbound vs Mounjaro: A UK Guide to the Same Drug, Different Brands

Zepbound and Mounjaro are the same drug — tirzepatide — manufactured by Eli Lilly and delivered in almost identical pens. The difference is purely regulatory: Zepbound is the US brand name for weight management use, Mounjaro is the global brand name (used in the UK, Europe, and originally for type 2 diabetes in the US). For UK residents, this post is most useful if you’re trying to understand international coverage, travel considerations, or US-based weight loss content that mentions Zepbound.

For the UK access pathway see How to Get Mounjaro in the UK. For related comparisons: Tirzepatide vs Semaglutide UK.

The short answer

Zepbound and Mounjaro contain identical active ingredient (tirzepatide), in identical doses, with identical pens. The brand names reflect different regulatory licensing:

• Mounjaro: originally licensed for type 2 diabetes treatment; later extended to weight management in several countries (UK, EU, others). This is the brand name used everywhere outside the US for both indications.
• Zepbound: a US-specific brand name launched in 2023 for weight management indication specifically. In the US, Mounjaro remains the brand for diabetes; Zepbound is the weight-management equivalent.

In the UK, you won’t be prescribed Zepbound — it’s not a UK brand. You’ll be prescribed Mounjaro for both diabetes and weight management use.

Why two different brands for the same drug?

Three reasons:

1. Regulatory approval pathways differ by indication. In the US, separate licensing for weight management requires distinct clinical trial data and regulatory review from the diabetes license. Even when the drug is the same, the approved indication matters for prescribing and insurance coverage.

2. Insurance and coverage considerations in the US. US health insurance commonly covers diabetes medications but doesn’t always cover weight management. Separating brand names allows insurers to clearly distinguish covered (Mounjaro for diabetes) from often-not-covered (Zepbound for weight management) prescriptions.

3. Marketing and consumer positioning. Eli Lilly markets Zepbound with a weight-management focus; Mounjaro with both diabetes and weight-management messaging in regions where it’s approved for both. Different names help targeted marketing.

In the UK, MHRA approved Mounjaro for weight management in 2023 under the same brand name, so there’s no need for a UK-specific “Zepbound equivalent.”

Are the pens identical?

Nearly identical, with small regional labelling differences:

• Active ingredient: tirzepatide, identical molecular structure, identical concentration per dose
• Pen mechanism: same single-dose auto-injector pen
• Dose strengths: same range (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg)
• Injection technique: identical
• Storage requirements: same refrigeration requirements
• Packaging: different branding, box design, patient information leaflet language
• Labelling: different regulatory markings and country-specific information

If you take a Mounjaro pen from the UK to the US, it will work identically to a Zepbound pen sold in the US. Travel with original packaging and prescription documentation to avoid border or pharmacy confusion.

Clinical effects: are they the same?

Yes. Same active ingredient, same doses, same effects:

• Same appetite suppression and food noise reduction
• Same weight loss trajectory (average 15–22% weight loss at 72 weeks in clinical trials)
• Same side effect profile (nausea, constipation, reflux, rare pancreatitis and gallbladder issues)
• Same dose titration schedule
• Same contraindications

Any content you read about Zepbound’s clinical effects applies directly to Mounjaro and vice versa.

If you’re reading US-based content

A lot of online GLP-1 content originates in the US, where Zepbound is the weight-management brand. When you read:

• “I’m on Zepbound 10mg” = same as “I’m on Mounjaro 10mg for weight management”
• “Zepbound side effects” = same side effects as Mounjaro
• “Zepbound vs Wegovy” = Mounjaro vs Wegovy; same comparison
• “Zepbound shortage news” = affects US supply; UK supply separate but same manufacturer

UK residents should consume this content freely but adjust naming when discussing with UK prescribers or pharmacists.

Travel considerations

UK residents travelling to the US

Travelling with Mounjaro to the US:

• Carry pens in original packaging with prescription documentation
• Mention the medication at customs if asked; show prescription
• US pharmacies will recognise Mounjaro (it’s licensed in the US for diabetes) but cannot dispense a replacement without a US prescription
• Emergency refill in the US requires either: US-licensed prescriber assessment (costly out-of-pocket), telehealth with a US provider, or waiting until you return home
• Plan supply carefully; don’t run out mid-trip

US residents on Zepbound travelling to the UK

The mirror scenario:

• Zepbound travels fine with original packaging and prescription
• UK pharmacies will recognise it as equivalent to Mounjaro but cannot dispense without a UK prescription
• Emergency refills require UK telehealth or private clinic assessment
• Private UK provider pricing applies (£150–£330 per month range)

See Mounjaro Travel Guide UK for broader travel logistics.

Cost comparison: UK vs US

A common question from UK residents:

• UK private Mounjaro: £150–£330 per month depending on dose and provider
• UK NHS Mounjaro (if eligible): prescription charge only (~£9.90 per item)
• US Zepbound retail (without insurance): approximately $1,000–$1,200 per month (~£800–£950)
• US Zepbound with insurance coverage (varies wildly): $0 to $400 per month out of pocket
• US Zepbound with Eli Lilly discount card (for uninsured): varies; typically $550–$650

UK private prices are substantially lower than US retail, which partly reflects different healthcare system economics. UK residents have no financial reason to source Zepbound internationally; domestic Mounjaro is both cheaper and more accessible.

Supply considerations

Tirzepatide has faced global supply constraints since 2023. US and UK supply are managed separately by Eli Lilly:

• Some dose strengths have been in shortage in the US at times when UK supply was adequate
• UK has experienced dose-strength shortages at different times
• Cross-border sourcing is not a reliable solution — each region’s regulated supply is prescribed locally

If UK supply is constrained, the solutions are domestic: discussing alternative doses with your prescriber, using different regulated providers, or temporarily switching medications. Attempting to source from the US is not practical for most UK users.

Can I use Zepbound from the US if I’m a UK resident?

Practically and legally, this is complicated:

Legally: importing prescription medication into the UK without a UK prescription is generally not permitted. Small quantities for personal use imported from an EU pharmacy have some grey-area legality; importing from the US is more clearly problematic.

Practically: US pharmacies won’t ship Zepbound to UK addresses without US prescription verification. Online “international pharmacies” offering Zepbound shipping to UK are often either illegitimate or dealing in counterfeit product. See Fake Mounjaro UK.

Financially: even if possible, US Zepbound costs more than UK Mounjaro. Shipping and import issues add further cost.

Clinically: you’d be using prescription medication without a UK prescriber relationship — no monitoring, no support for side effects, no emergency contact.

For UK residents, use UK channels. There’s no clinical or financial benefit to sourcing from the US.

Why does this matter in the UK?

Three reasons this post exists despite Zepbound not being a UK brand:

1. Information confusion. UK users reading US-based forums, YouTube content, or news articles encounter “Zepbound” frequently. Clear understanding that this is just Mounjaro prevents confusion.

2. Travel. UK residents travelling to the US or US residents visiting the UK need to know the name maps straightforwardly.

3. Future US family members or visitors. If a family member in the US is on Zepbound, you now know you’re comparing like with like if you’re also on Mounjaro.

Will the brand situation change?

Possibly. Some scenarios:

• If the US unifies weight-management and diabetes branding (unlikely soon), Zepbound could eventually merge with Mounjaro
• If UK licensing changes separate weight management and diabetes branding, we might see a UK-specific weight management brand (currently unlikely)
• As tirzepatide patents expire (starting in early 2030s), generic tirzepatide brands may appear in various regions

For now, the status quo is stable: Mounjaro in UK, Zepbound for weight management in US, same drug in both.

Additional context worth knowing

Clinical trials: where the evidence comes from

Both brands draw on the same underlying clinical trial programme:

• SURMOUNT-1 to SURMOUNT-4: Eli Lilly’s weight management trials with tirzepatide. These are the foundation of both Mounjaro’s UK weight management licensing and Zepbound’s US licensing. Same drug, same data, same conclusions.
• SURPASS programme: tirzepatide for type 2 diabetes. Underpins both Mounjaro’s diabetes licensing in the UK/US and the historic brand identity.

When you see research quoted about “tirzepatide,” “Mounjaro,” or “Zepbound,” it’s almost always drawing from these shared trial datasets.

Supply, shortages, and brand allocation

Eli Lilly has produced tirzepatide for three indications across two brands:

• Mounjaro for diabetes (global)
• Mounjaro for weight management (UK, EU, selected markets)
• Zepbound for weight management (US only)

Production constraints have meant certain dose strengths have been prioritised for certain indications or regions at times. A user in the US on Zepbound during an acute shortage may find 10mg unavailable while 7.5mg is accessible; a UK user on Mounjaro during a different production cycle may face the reverse. These issues resolve over time but can be frustrating during shortages.

Insurance nuances (for US readers)

Though not a UK concern, worth flagging: US insurance coverage for weight management medications is notoriously variable. Many US insurance plans cover Mounjaro (diabetes) but exclude Zepbound (weight management) because weight-management drugs are often categorised as “lifestyle” rather than medical necessity. This has created a documented phenomenon in the US of some patients being prescribed Mounjaro for borderline diabetes indications to access coverage that Zepbound wouldn’t receive. Not a UK issue since NHS and private UK channels don’t structure coverage this way.

The Eli Lilly product family

Helpful context for understanding brand names:

• Mounjaro / Zepbound: tirzepatide (GLP-1 + GIP dual agonist)
• Trulicity: dulaglutide (older GLP-1 single agonist, weekly injection, for diabetes)
• Retatrutide: triple agonist (GLP-1 + GIP + glucagon), in Phase 3 trials, potential future approval for weight management
• Orforglipron: oral non-peptide GLP-1 agonist in Phase 3 trials

Eli Lilly’s metabolic medicine pipeline is extensive; Mounjaro/Zepbound is the current flagship, but more is coming.

Quick myth-busting

Claims to be sceptical of:

“Zepbound is stronger than Mounjaro.” False. Same drug, same strength.

“Zepbound has fewer side effects than Mounjaro.” False. Identical.

“Zepbound is Mounjaro’s replacement.” False. They coexist; different brands for different regions/indications.

“Zepbound is approved for weight loss but Mounjaro isn’t.” False in UK and Europe (Mounjaro is approved for weight management); partially true only for US (where Zepbound is weight-management brand, Mounjaro is diabetes brand).

“Zepbound works better for weight loss because it’s formulated for it.” False. Same formulation.

“Zepbound is easier to get than Mounjaro.” Region-dependent. In the UK, Mounjaro is what’s accessible. In the US, both are available but with different insurance coverage.

For US readers wondering about Mounjaro

Flipping the perspective: US residents reading UK GLP-1 content encounter “Mounjaro for weight management” frequently and may wonder why their doctor said “Zepbound.” Answer: same drug, different brand based on your insurance coverage pathway. If your insurance covers Mounjaro for diabetes (if you have type 2 diabetes) but not Zepbound for weight management, the prescribing name matters for coverage; the drug effect is identical.

The summary

Zepbound and Mounjaro are the same drug (tirzepatide) with different brand names based on region and indication. UK residents get Mounjaro; US residents get Zepbound for weight management or Mounjaro for diabetes. Content about one applies directly to the other. No clinical reason to prefer one brand over the other — the question is simply which one your prescription pathway uses.

For the UK access route: How to Get Mounjaro in the UK. For related drug comparisons: Tirzepatide vs Semaglutide UK, Ozempic vs Wegovy UK.

Medical note: this is general information about drug branding. Clinical questions about which medication is right for you should be discussed with your prescriber.